Hans-Christian Kolberg, MD, head of the department of obstetrics and gynecology, breast cancer center, and gynecologic cancer center at Marienhospital Bottrop, Germany, reflects on the importance of reporting new cardiac data from the LILAC trial of ABP 980, a trastuzumab biosimilar.
Transcript
I think it is very important to keep reporting these things because, even for people doing oncology for years and decades, it’s still very difficult to really differentiate between a generic medication and a biosimilar. A generic is simply like cooking the same recipe, and developing a biosimilar is completely different. It’s really developing a new medication; you just do it the other way around. It is reverse-engineering because you have to find out what the original company was doing.
The effect regarding healthcare economics is that, of course, you can sell that cheaper because developing a new antibody is an investment of more than $1 billion usually, whereas developing a biosimilar for a known antibody costs about $200 million dollars.
So actually the prices in the end are cheaper, which is of course important in countries like the United States or in Germany, where I work, because we save money we can use for other things in the healthcare system. But it's even more important in places where giving a patient an antibody is not a question because there's no money for that. Like in the developing countries. For those, biosimilars may be a huge chance to gain access to antibodies at all.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.